| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Baker Medical Research Institute and Alfred Hospital, Victoria, Australia 3181
Address all correspondence and requests for reprints to: Associate Professor Paul Komesaroff, Baker Medical Research Institute, P.O. Box 6492, St. Kilda Road Central, Melbourne, Victoria, Australia 8008. E-mail: paul.komesaroff{at}baker.edu.au
Dehyroepiandrosterone (DHEA), an adrenal-derived steroid, has been clinically implicated in protection against coronary artery disease and experimentally in inhibition of atherosclerosis and plaque progression. Because DHEA is enzymatically metabolized to androgens or estrogens, it is not clear whether DHEA exerts effects directly or after conversion to these hormones, both of which are associated with well-characterized pathways of action. We therefore examined the effects of DHEA on proliferation of human vascular smooth muscle cells (VSMCs) in culture in the presence or absence of the ER antagonist ICI 182,780 and the AR antagonist flutamide and compared them with the effects of 17ß-estradiol, androstenedione, and T. We also determined the affinity of DHEA for ERs and ARs in VSMC and its specific binding in intact cells. To explore a possible mechanism for DHEA action in these cells, we measured the phosphorylation of ERK-1, c-jun N-terminal protein kinase, and p38 (three members of the MAPK superfamily). Both DHEA and 17ß-estradiol significantly inhibited platelet derived growth factor (PDGF)-BB-induced increases in VSMC proliferation, whereas androstenedione and T increased proliferation. Although E2-induced inhibition of the PDGF effect was abolished by ICI 182,780 and T-induced stimulation was abolished by flutamide, neither receptor antagonist altered the inhibitory effect of DHEA. Binding studies confirmed the presence of both ERs and ARs; DHEA showed minimal affinity for either receptor but bound specifically and with high affinity to putative receptors in intact cells. Following 4-h incubation with DHEA (1100 nM), ERK1 phosphorylation was significantly reduced in a dose-dependent manner, whereas neither c-jun N-terminal protein kinase nor p38 kinase activity was altered by either PDGF-BB or DHEA. DHEA inhibits human VSMC proliferation by a mechanism independent of either ARs or ERs, presumably via a DHEA-specific receptor that involves ERK1 signaling pathways.
Abbreviations: DHEA, Dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; IMA, internal mammary artery; JNK, c-jun N-terminal protein kinase; PDGF, platelet derived growth factor; VSMC, vascular smooth muscle cell.
This article has been cited by other articles:
![]() |
A. Aversa, R. Bruzziches, D. Francomano, M. Natali, and A. Lenzi Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Therapeutic Advances in Urology, October 1, 2009; 1(4): 179 - 197. [Abstract] [PDF] |
||||
![]() |
S. Bonnet, R. Paulin, G. Sutendra, P. Dromparis, M. Roy, K. O. Watson, J. Nagendran, A. Haromy, J. R.B. Dyck, and E. D. Michelakis Dehydroepiandrosterone Reverses Systemic Vascular Remodeling Through the Inhibition of the Akt/GSK3-{beta}/NFAT Axis Circulation, September 29, 2009; 120(13): 1231 - 1240. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Komesaroff Unravelling the Enigma of Dehydroepiandrosterone: Moving Forward Step by Step Endocrinology, March 1, 2008; 149(3): 886 - 888. [Full Text] [PDF] |
||||
![]() |
D. Liu, M. Iruthayanathan, L. L. Homan, Y. Wang, L. Yang, Y. Wang, and J. S. Dillon Dehydroepiandrosterone Stimulates Endothelial Proliferation and Angiogenesis through Extracellular Signal-Regulated Kinase 1/2-Mediated Mechanisms Endocrinology, March 1, 2008; 149(3): 889 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Ziegler, F. Sicard, P. Lattke, S. R. Bornstein, M. Ehrhart-Bornstein, and A. W. Krug Dehydroepiandrosterone Induces a Neuroendocrine Phenotype in Nerve Growth Factor-Stimulated Chromaffin Pheochromocytoma PC12 Cells Endocrinology, January 1, 2008; 149(1): 320 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Liu, H. Si, K. A. Reynolds, W. Zhen, Z. Jia, and J. S. Dillon Dehydroepiandrosterone Protects Vascular Endothelial Cells against Apoptosis through a G{alpha}i Protein-Dependent Activation of Phosphatidylinositol 3-Kinase/Akt and Regulation of Antiapoptotic Bcl-2 Expression Endocrinology, July 1, 2007; 148(7): 3068 - 3076. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oka, V. Karoor, N. Homma, T. Nagaoka, E. Sakao, S. M. Golembeski, J. Limbird, M. Imamura, S. A. Gebb, K. A. Fagan, et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension Cardiovasc Res, June 1, 2007; 74(3): 377 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, Y.-D. Wang, W.-J. Wang, Y. Zhu, and D.-J. Li Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor J. Mol. Endocrinol., April 1, 2007; 38(4): 467 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Arlt, F. Hammer, P. Sanning, S. K. Butcher, J. M. Lord, B. Allolio, D. Annane, and P. M. Stewart Dissociation of Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Septic Shock J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2548 - 2554. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Dagre, J Lekakis, C Mihas, A Protogerou, L Thalassinou, D Tryfonopoulos, G Douridas, C Papamichael, and M Alevizaki Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2006; 154(6): 883 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Natoli, T. L. Medley, A. A. Ahimastos, B. G. Drew, D. J. Thearle, R. J. Dilley, and B. A. Kingwell Sex Steroids Modulate Human Aortic Smooth Muscle Cell Matrix Protein Deposition and Matrix Metalloproteinase Expression Hypertension, November 1, 2005; 46(5): 1129 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakamura, M. Yoshimura, M. Nakayama, T. Ito, Y. Mizuno, E. Harada, T. Sakamoto, Y. Saito, K. Nakao, H. Yasue, et al. Possible Association of Heart Failure Status With Synthetic Balance Between Aldosterone and Dehydroepiandrosterone in Human Heart Circulation, September 28, 2004; 110(13): 1787 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. I. Williams, T. Dawood, S. Ling, A. Dai, R. Lew, K. Myles, J. W. Funder, K. Sudhir, and P. A. Komesaroff Dehydroepiandrosterone Increases Endothelial Cell Proliferation in Vitro and Improves Endothelial Function in Vivo by Mechanisms Independent of Androgen and Estrogen Receptors J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4708 - 4715. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Iwasaki, M. Asai, M. Yoshida, T. Nigawara, M. Kambayashi, and N. Nakashima Dehydroepiandrosterone-Sulfate Inhibits Nuclear Factor-{kappa}B-Dependent Transcription in Hepatocytes, Possibly through Antioxidant Effect J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3449 - 3454. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Littleton-Kearney and P. D. Hurn Testosterone as a Modulator of Vascular Behavior Biol Res Nurs, April 1, 2004; 5(4): 276 - 285. [Abstract] [PDF] |
||||
![]() |
F. Pizzagalli, Z. Varga, R. D. Huber, G. Folkers, P. J. Meier, and M. V. St-Pierre Identification of Steroid Sulfate Transport Processes in the Human Mammary Gland J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3902 - 3912. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Simoncini, P. Mannella, L. Fornari, G. Varone, A. Caruso, and A. R. Genazzani Dehydroepiandrosterone Modulates Endothelial Nitric Oxide Synthesis Via Direct Genomic and Nongenomic Mechanisms Endocrinology, August 1, 2003; 144(8): 3449 - 3455. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kawano, H. Yasue, A. Kitagawa, N. Hirai, T. Yoshida, H. Soejima, S. Miyamoto, M. Nakano, and H. Ogawa Dehydroepiandrosterone Supplementation Improves Endothelial Function and Insulin Sensitivity in Men J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3190 - 3195. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |